Ozone Therapy for Cancer Therapy-Related Oral Mucositis (OMUC-O3)
Retrospective Evaluation of Combined Chairside and Domiciliary Ozone Therapy for the Management of Cancer Therapy-Related Oral Mucositis
This retrospective observational study will evaluate clinical data already available from adult cancer patients who developed cancer therapy-related oral mucositis during radiotherapy and/or chemotherapy and who were managed in routine clinical practice with combined chairside and domiciliary ozone therapy.
The study will not assign participants to any treatment and will not involve any new intervention, visit, examination, or change in patient care. Data will be extracted from existing medical records and clinical documentation.
The main purpose of the study is to describe the clinical course of oral mucositis and to evaluate the time needed to reach oral mucositis grade 1 or lower according to the World Health Organization Oral Toxicity Scale. The study will also assess changes in oral pain intensity, measured using a 0 to 10 Visual Analogue Scale, from baseline to follow-up visits up to 15 days.
Exploratory analyses will compare clinical trends between patients with head and neck cancers and patients with cancers in other anatomical sites. The results will be interpreted as descriptive and exploratory because the study is retrospective, single-arm, and has no control group.
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Descrição detalhada
Oral mucositis is a clinically relevant complication of anticancer treatments, especially radiotherapy and chemotherapy. It can cause erythema, ulcerations, oral pain, dysphagia, impaired oral intake, and reduced quality of life. In routine clinical practice, selected patients with cancer therapy-related oral mucositis were managed with a combined ozone-based protocol including professional chairside ozone application and domiciliary ozonized oral care products.
This study is designed as a retrospective observational analysis of data already available from medical records and clinical documentation. No prospective enrollment, treatment allocation, randomization, study-specific intervention, biological sampling, imaging, or additional clinical visit will be performed.
The study will include adult oncological patients with documented cancer therapy-related oral mucositis grade 1 or higher according to the World Health Organization Oral Toxicity Scale. Available data will include demographic and clinical information, oncological disease site, oral mucositis severity, and oral pain intensity measured using a 0 to 10 Visual Analogue Scale.
The retrospective observation period includes clinical data collected during routine care between November 2023 and September 2025. Outcome data will be analyzed from baseline to available follow-up visits up to 15 days. Additional exploratory analyses will describe clinical trends according to cancer site, comparing patients with head and neck cancers with patients with malignancies in other anatomical sites.
The findings will be interpreted as descriptive and exploratory, because the study is retrospective, single-arm, and does not include a control group.
Tipo de estudo
Inscrição (Real)
Contactos e Locais
Locais de estudo
-
-
Lombardy
-
Pavia, Lombardy, Itália, 27100
- Section of Dentistry - Department of Clinical, Surgical, Diagnostic and Paediatrics - University of Pavia
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
- Adulto
- Adulto mais velho
Aceita Voluntários Saudáveis
Método de amostragem
População do estudo
Descrição
Inclusion Criteria:
- Age 18 years or older
- Oncological patients undergoing radiotherapy and/or chemotherapy
- Clinical diagnosis of cancer therapy-related oral mucositis grade 1 or higher according to the World Health Organization Oral Toxicity Scale
- Availability of clinical documentation including World Health Organization Oral Toxicity Scale assessments and Visual Analogue Scale pain scores at baseline and at one or more follow-up timepoints
- Availability of relevant demographic and clinical information required for the retrospective analysis
Exclusion Criteria:
- Age younger than 18 years
- Absence of a documented diagnosis of cancer therapy-related oral mucositis
- Incomplete or unavailable clinical documentation for the primary and/or main secondary outcome
- Missing baseline World Health Organization Oral Toxicity Scale assessment
- Missing baseline Visual Analogue Scale pain assessment
- Any condition making the available data unsuitable for retrospective analysis
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
Coortes e Intervenções
Grupo / Coorte |
Intervenção / Tratamento |
|---|---|
|
Cancer Therapy-Related Oral Mucositis Cohort
Adult oncological patients with documented cancer therapy-related oral mucositis grade 1 or higher according to the World Health Organization Oral Toxicity Scale.
Patients were previously managed in routine clinical practice with a combined ozone-based protocol including professional chairside ozone application and domiciliary ozonized oral care products.
This is a retrospective observational cohort; no treatment assignment, randomization, or study-specific intervention will be performed.
|
Adult oncological patients with cancer therapy-related oral mucositis were previously managed in routine clinical practice with a combined ozone-based oral care protocol.
The protocol included professional chairside ozone application to oral mucosal lesions using an ozone device with a mucosa-specific probe, followed by domiciliary use of ozonized oral care products, including ozonized hydrogel, toothpaste, and mouthwash, according to routine clinical instructions.
In this retrospective observational study, no intervention will be assigned or performed for research purposes, and no change to patient management is planned.
Outros nomes:
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Time to Achieve Oral Mucositis Grade 1 or Lower
Prazo: At baseline before ozone therapy (T0), immediately after the first professional ozone application (T1), 48 hours after T1 (T2), 5 days after T1 (T3), 8 days after T1 (T4), 12 days after T1 (T5), and 15 days after T1 (T6)
|
Time, expressed in days, required to achieve oral mucositis grade 1 or lower according to the World Health Organization Oral Toxicity Scale.
The outcome will be assessed retrospectively using clinical data already available from medical records and clinical documentation.
Patients who did not reach WHO grade 1 or lower by the last available follow-up will be censored at their last valid assessment.
|
At baseline before ozone therapy (T0), immediately after the first professional ozone application (T1), 48 hours after T1 (T2), 5 days after T1 (T3), 8 days after T1 (T4), 12 days after T1 (T5), and 15 days after T1 (T6)
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Change in Oral Pain Intensity
Prazo: At baseline before ozone therapy (T0), immediately after the first professional ozone application (T1), 48 hours after T1 (T2), 5 days after T1 (T3), 8 days after T1 (T4), 12 days after T1 (T5), and 15 days after T1 (T6)
|
Absolute change in oral pain intensity from baseline to the end of follow-up, assessed using a Visual Analogue Scale from 0 to 10, where higher scores indicate greater pain intensity.
The outcome will be assessed retrospectively using clinical data already available from medical records and clinical documentation.
|
At baseline before ozone therapy (T0), immediately after the first professional ozone application (T1), 48 hours after T1 (T2), 5 days after T1 (T3), 8 days after T1 (T4), 12 days after T1 (T5), and 15 days after T1 (T6)
|
|
Change in Oral Mucositis Severity Over Time
Prazo: At baseline before ozone therapy (T0), immediately after the first professional ozone application (T1), 48 hours after T1 (T2), 5 days after T1 (T3), 8 days after T1 (T4), 12 days after T1 (T5), and 15 days after T1 (T6)
|
Change in oral mucositis severity across the available follow-up timepoints, assessed using the World Health Organization Oral Toxicity Scale.
Scores will be extracted retrospectively from existing clinical documentation at baseline and follow-up visits.
Lower scores indicate lower oral mucositis severity.
|
At baseline before ozone therapy (T0), immediately after the first professional ozone application (T1), 48 hours after T1 (T2), 5 days after T1 (T3), 8 days after T1 (T4), 12 days after T1 (T5), and 15 days after T1 (T6)
|
|
Change in Oral Pain Intensity Over Time
Prazo: At baseline before ozone therapy (T0), immediately after the first professional ozone application (T1), 48 hours after T1 (T2), 5 days after T1 (T3), 8 days after T1 (T4), 12 days after T1 (T5), and 15 days after T1 (T6)
|
Change in oral pain intensity across the available follow-up timepoints, assessed using a Visual Analogue Scale from 0 to 10. Scores will be extracted retrospectively from existing clinical documentation at baseline and follow-up visits.
Higher scores indicate greater pain intensity.
|
At baseline before ozone therapy (T0), immediately after the first professional ozone application (T1), 48 hours after T1 (T2), 5 days after T1 (T3), 8 days after T1 (T4), 12 days after T1 (T5), and 15 days after T1 (T6)
|
|
Oral Mucositis Severity Trends by Cancer Site
Prazo: At baseline before ozone therapy (T0), immediately after the first professional ozone application (T1), 48 hours after T1 (T2), 5 days after T1 (T3), 8 days after T1 (T4), 12 days after T1 (T5), and 15 days after T1 (T6)
|
Exploratory comparison of oral mucositis severity trends between patients with head and neck cancers and patients with malignancies in other anatomical sites, assessed using the World Health Organization Oral Toxicity Scale across the available retrospective follow-up timepoints.
|
At baseline before ozone therapy (T0), immediately after the first professional ozone application (T1), 48 hours after T1 (T2), 5 days after T1 (T3), 8 days after T1 (T4), 12 days after T1 (T5), and 15 days after T1 (T6)
|
|
Oral Pain Intensity Trends by Cancer Site
Prazo: At baseline before ozone therapy (T0), immediately after the first professional ozone application (T1), 48 hours after T1 (T2), 5 days after T1 (T3), 8 days after T1 (T4), 12 days after T1 (T5), and 15 days after T1 (T6)
|
Exploratory comparison of oral pain intensity trends between patients with head and neck cancers and patients with malignancies in other anatomical sites, assessed using a Visual Analogue Scale from 0 to 10 across the available retrospective follow-up timepoints.
Higher scores indicate greater pain intensity.
|
At baseline before ozone therapy (T0), immediately after the first professional ozone application (T1), 48 hours after T1 (T2), 5 days after T1 (T3), 8 days after T1 (T4), 12 days after T1 (T5), and 15 days after T1 (T6)
|
Colaboradores e Investigadores
Patrocinador
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Real)
Conclusão do estudo (Real)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- 2026-OMUC-O3
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Descrição do plano IPD
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .